Prof. Dr. Ciro Isidoro

Dr. Ciro Isidoro is Full Professor of General Pathology and Clinical Pathology at the Department of Health Sciences, Università del Piemonte Orientale (Novara, Italy). His laboratory has a consolidated experience in the biogenesis and function of lysosomal proteases, and in alterations of the autophagy-lysosomal proteolysis in cancer. Emphasis is given to the study of protein–protein interactions and to the subcellular localization of the protein of interest in order to understand its altered function. Researches focus on the mechanism of action of nutraceuticals and probiotics in the epigenetic regulation of autophagy and of cell death in 3D heterotypic organoid cancer models.

Dr. Jacques Pouyssegur

Over the last 35 years, Pouyssegur’s team has made substantial contributions to the areas of cell adhesion, surface glycoproteins, metabolism, intracellular pH control, first structure of human Na/H antiporter (NHE1) and established that pHi and MAP kinase (ERK1/2) signaling are critical for cell cycle entry. During the last 15 years the group has turned his interest to another essential growth mechanism: how do cells control their nutrient supply? This key process has led him to investigate mechanisms of hypoxia signaling, angiogenesis, tumor metabolism, nutritional and oxidative stresses in cancer.

Prof. Dr. Danny N. Dhanasekaran

Dr. Danny Dhanasekaran received his Ph.D. in Biochemistry from the Indian Institute of Science, India and postdoctoral training at the University of Wisconsin-Madison, Wisconsin and National Jewish Center for Cancer Research and Respiratory Medicine at Denver, Colorado. After rising to the rank of Professor of Biochemistry at Temple University School of Medicine, Philadelphia, he joined the University of Oklahoma Health Science Center as the Professor of Cell Biology, Samuel Noble Foundation Endowed Chair in Cancer Research, and Deputy Director for Basic Research of the Stephenson Cancer Center. His academic honors include WCU Professorship at the Seoul National University, Seoul, S. Korea, Visiting Professor of Tokyo Medical and Dental University, Tokyo, Japan, and Visiting Professorship in Università del Piemonte Orientale, Novara, Italy. He has published more than 100 peer-reviewed publications. His current research is focused on defining the role of coding and non-coding RNAs in tumor microenvironment and tumor progression along with a focus on developing novel cancer therapeutics.

Prof. Dr Salem Chouaib

Prof. Salem Chouaib, an INSERM Research Director at Institute Gustave Roussy, Paris, France, completed his undergraduate studies at the university Pierre and Marie Curie (Paris VI) and Pasteur Institute (Paris). He received his PhD in immunology, (laboratory of Jean Dausset, Nobel prize in medicine) in 1983 and his higher doctorate (doctorat d etat es sciences) in 1986 from the same university. He joined the Memorial Sloan Kettering Cancer Center in New York where he undertook a post-doctoral training in the Human Immunogenetics Laboratory. In 1986, he was appointed as research associate at the French National Institute of Health and Biomedical Research (INSERM) and joined the tumor biology department at the Institut Gustave Roussy. For more than twenty years, he was leading an INSERM Research Unit (tumor immunology). His laboratory focused on the investigation of the functional cross talk between cytotoxic cells and tumor targets in the context of tumor microenvironment complexity and plasticity. His research was constantly directed at impulsing the transfer of fundamental concepts in clinical application in particular in the field of cancer vaccine and cancer immunotherapy.

Keynote

Dr. Jacques Pouyssegur

"Exploiting Metabolism, Nutritional and Oxidative Stresses in Cancers"

3.00pm

Q&A (10 min)

Prof. Dr. Danny N. Dhanasekaran

"LncRNAs and Cancer Epigenome"

3.50pm

Q&A (10 min)

Prof. Dr. Salem Chouaib
Pleas note that Dr. Stephane Terry will be presenting on Prof. Dr. Chouaib's behalf.

"Impact of microenvirnmental hypoxic stress on the anti-tumor cytotoxic response."

4.25pm

Q&A (10 min)